CSIMarket
 
Cervomed Inc   (CRVO)
Other Ticker:  
 
 
Price: $15.9500 $0.02 0.126%
Day's High: $16.42 Week Perf: 3.17 %
Day's Low: $ 15.43 30 Day Perf: -19.49 %
Volume (M): 76 52 Wk High: $ 26.38
Volume (M$): $ 1,207 52 Wk Avg: $15.78
Open: $16.03 52 Wk Low: $5.85



 Market Capitalization (Millions $) 98
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Cervomed Inc
Cervomed Inc is a medical technology company that specializes in developing and manufacturing devices for the treatment of neurological disorders. The company's focus is on designing innovative solutions to improve the quality of life for patients suffering from conditions such as chronic pain, epilepsy, and movement disorders. Cervomed Inc aims to provide safe and effective products that utilize advanced technologies to address these neurological issues.


   Company Address: 20 Park Plaza, Suite 424 Boston 2116 MA
   Company Phone Number: 744-4400   Stock Exchange / Ticker: CRVO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

CervoMed's Appointment of William Elder as CFO Bolsters Future Prospects for Neurologic Disorders Treatment

Published Mon, May 20 2024 12:01 PM UTC

CervoMed's Strategic Appointment of William Elder as CFO Signals Promising Future for Neurologic Disorders Treatment
CervoMed Inc., a renowned clinical stage company dedicated to the development of treatments for age-related neurologic disorders, has recently announced a significant addition to its leadership team. William (Bill) Elder, currently serving as General Coun...

Management Announcement

CervoMed: Revolutionizing Healthcare with $149 Million in Major Funding

Published Thu, Mar 28 2024 12:30 PM UTC

CervoMed Secures Major Funding with Leading Healthcare Investors

In a recent development, CervoMed, a prominent player in the healthcare sector, has announced its successful completion of a private placement financing round, raising $149.4 million. This impressive investment comes from a group of esteemed investors including RA Capital Management, Armistice Capital,...

Clinical Study

Neflamapimod: A Promising Breakthrough in Tau-Mediated Disease - Biomarker Data from AscenD-LB Phase 2a Trial and Preclinical Studies Presented at AD/PD 2024

Published Tue, Mar 5 2024 1:00 PM UTC

CervoMed, a renowned pharmaceutical company, unveiled groundbreaking findings at the AD/PD 2024 conference regarding the potential of their drug candidate, Neflamapimod, in treating Tau-mediated diseases. These diseases, including Alzheimer's and Parkinson's, are characterized by the accumulation of abnormal tau protein in the brain, leading to cognitive decline and neurolog...

Clinical Study

Promising Results of Neflamapimod in Dementia with Lewy Bodies Reinforce Therapeutic Potential: Study Indicates Hope for Patients

Published Mon, Feb 12 2024 1:00 PM UTC

CervoMed, a renowned biopharmaceutical company, has recently published positive findings from the AscenD-LB Phase 2a trial in a reputable peer-reviewed journal. This critical breakthrough offers new hope for patients suffering from dementia with Lewy bodies (DLB). The study's integrated summary covered all previously published Phase 2a clinical results, further supported by ...






 

Cervomed Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cervomed Inc does not provide revenue guidance.

Earnings Outlook
Cervomed Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com